Open in interactive viewer → charts, metric popovers & call review

Talphera Asks the FDA to Let It Stop Trying

Enrollment fell 85–90% in three months, so a $54 million company with four quarters of cash has bet its timeline on a 45-day Sprint Meeting — and the stock already voted
TLPH · Earnings Call · 2026-11-12

The 45-day clock

Three months ago Talphera told investors the NEPHRO study of Niyad — an investigational nafamostat-based regional anticoagulant for the CRRT circuit — was past 75% enrolled and tracking to a second-half-2026 finish. On this call, the same 75% number appeared, but wrapped around a completely different story. Enrollment had collapsed. “Just compared with the same period in 2025, our number of patients consented and enrolled dropped by 85% to 90%.” — Shakil Aslam, Chief Medical Officer · 2026-11-12 The fix is procedural rather than clinical: management filed a briefing document requesting an FDA Sprint Meeting, a time-boxed 45-day feedback mechanism available to Breakthrough Device designees, to obtain the agency's agreement to close enrollment on December 31, 2026 at whatever N has accumulated. The company says the study is now over 80% powered for the primary endpoint versus the >90% it was designed for at 70 patients. This is a request for permission to stop early — early closure is the term that dominated the keyword set this quarter, and it is genuinely new vocabulary for this company. Ed Arce of WestPark Capital asked the question everyone was thinking:

So just to clarify on the number of patients, 3 months ago you had reported 75% enrollment and today, 3 months later you're saying it's over 75%. So, am I to understand that over the last 3 months you've maybe enrolled 2 or 3 patients.

Antonio Arce, Analyst · 2026-11-12
Vince Angotti's answer was that the company has enrolled patients "since our last update" and is "over 75% enrolled now without giving a specific number." That is not a denial.

What the tape already knew

The company is worth $53.7 million. Its shares have fallen 37.9% over the last ninety trading days — a single leg down from a $1.47 August peak, now sitting 38% below it — before this print. The market reached a verdict on enrollment momentum ahead of the disclosure, which is what you would expect from a stock whose entire equity value is a probability-weighted bet on one readout. Note the symmetry: the $200 million peak US sales estimate management now touts is roughly four times the market capitalization of the company making the claim. Bull case and bear case are simply disagreeing about the discount rate. Cash is the reason the timeline matters so much. The balance sheet had $14.2 million at September 30, plus roughly $16 million of conditional tranches that management expects to close "around the time we release our top line data." That gate is not decorative. Effective net cash of $12M is down 87% from the 2018 peak of $94M, and a cash runway of about 4.4 quarters leaves roughly zero margin for a slow FDA negotiation. The burn is modest at least: operating loss of roughly $4M per quarter means the constraint is regulatory timing, not profligacy.

The precedent trade

Give management this: the strongest part of the call was the specific precedent for stopping a CRRT trial early. Chief Medical Officer Shakil Aslam walked through three prior studies in this exact patient population — one Vantive/Baxter citrate study that enrolled 34 of a planned 160 over three years and was renegotiated down to 40 subjects, and Fresenius, which targeted 50 and settled for 31.

They reached back to the FDA and got their agreement to submit both their 510(k) as well as NDA... they were able to submit that data from those 31 subjects and they got approval of all of their products about 2 weeks ago.</inline_quote_placeholder>

Shakil Aslam, Chief Medical Officer · 2026-11-12
That is a real regulatory datapoint, and it does some work: it argues the enrollment failure is a property of the indication — critically ill ICU patients with >50–60% mortality and narrow consent windows — not of Niyad or of Talphera's execution. The company reinforces it with the New England Journal study that was halted early on higher mortality with intermittent hemodialysis versus CRRT, which, if anything, expands the addressable CRRT pool. But the argument cuts both ways. If three separate sponsors over a decade could not enroll a CRRT study, and if citrate — with 25–30% off-label share of CRRT anticoagulation — could not pull 50 patients from its own user base, then the difficulty of clinical trial enrollment is at least weakly informative about the difficulty of commercial penetration into the same concentrated set of institutions. Angotti countered that the trial-to-market translation doesn't hold because of qualifying protocols and consent requirements. “Clinical trial environment really can't be translated into the real world due to the qualifying protocols, the consents required.” — Vincent Angotti, Chief Executive Officer · 2026-11-12 Plausible. Unproven. And the investor event that was supposed to detail the market research has slipped to the first quarter of 2027 — after the readout, not before.

The word that keeps coming back

The most revealing phrase on the call wasn't new at all. “We've always said that the enrollment is erratic.” — Vincent Angotti, Chief Executive Officer · 2026-11-12 He's right, and that's the problem. In May 2026: “The study goes in ebbs and flows.” — Vincent Angotti, Chief Executive Officer · 2026-05-13 In August 2025, describing the new nephrologist-led site profile: “The rates of enrollment are significantly increasing.” — Vincent J. Angotti, Chief Executive Officer · 2025-08-14 By November 2025, asked whether the new sites enrolled faster: “They're enrolling about the same rate.” — Vincent J. Angotti, Chief Executive Officer · 2025-11-12 The pattern of acceleration-then-stall has now repeated through at least four calls. The management response has shifted from "add more sites" (2025) to "renegotiate with the FDA" (2026). What has quietly dropped out of the narrative is equally telling. KDIGO guideline language — the draft update elevating nafamostat as an alternative anticoagulant — was the single highest-momentum theme for this company last quarter and now sits among the quarter's fading keywords. Heparin and citrate supply chain shortages, a recurring bull talking point through 2025, went unmentioned. When the catalyst deck shrinks to a regulatory precedent and a market-research number that won't be detailed until 2027, that's a story about a company running out of new things to say. The global context offers a thin but real echo: Kidney Care National Plan surfaced in this quarter's market-wide top keywords and was picked up by dialysis-exposed reporters including RMTI and HNSA.ST. Renal care policy is in the air. It just isn't obviously monetizable for a pre-approval single-asset company with a December deadline.

The honest framing

This is now a binary, near-dated event with a clean setup: FDA feedback by year-end, blinded data preserved, topline four to six weeks after enrollment closes, PMA in 2027, and a Breakthrough pathway that compresses review to six months. Management was explicit that a "no" simply means continuing to 70 patients and pushing into the first quarter — a one-quarter slip that happens to land squarely on the financing tranches. “We would continue on as is until we achieve the 70 patients.” — Vincent Angotti, Chief Executive Officer · 2026-11-12 The bull case requires believing that a 45-day meeting goes well and that >80% power on a blinded dataset is enough for a PMA reviewer who already accepted a reduction from 166 to 70 patients. The bear case is that "over 75%" three months running is a euphemism, that the cash runway and the tranche conditions land in the same quarter, and that the stock has already made its call.